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Abstract Hepatitis C virus (HCV) is a major etiologic agent
for chronic hepatitis worldwide often leading to the development
of cirrhosis and hepatocellular carcinoma. However, the mech-
anism for development of chronic hepatitis or hepatocarcinogen-
esis by HCV remains unclear. HCV NS5A protein possesses
many intriguing properties, including sequestration of p53 in
the cytoplasm, downregulation of p21 protein, activation of
STAT3, and inhibition of tumor necrosis factor-K-mediated ap-
optosis. Thus, we investigated whether this viral protein has
oncogenic property in vivo. In the absence of an e⁄cient cell
culture system for virus growth and a suitable small animal
model for HCV infection, transgenic FVB mice were generated
by targeting the HCV NS5A genomic region cloned under the
control of a liver-speci¢c apoE promoter or mouse major uri-
nary promoter (MUP). The apoE promoter is constitutively ex-
pressed in liver, on the other hand, the MUP is developmentally
regulated and expressed in the liver after birth. Reverse tran-
scription polymerase chain reaction and Western blot analysis
indicated establishment of HCV NS5A transgene expression in
several lines from both groups of mice. Immunohistochemical
studies suggested the presence of NS5A in the cytoplasm of
hepatocytes. The transgenic animals were phenotypically similar
to their normal littermates and did not exhibit a major histo-
logical change within the liver up to 24 months of age. Our
results suggested HCV NS5A protein is not directly cytopathic
or oncogenic in this FVB transgenic mouse model, although this
viral protein promotes cell growth in vitro. These animals will be
a valuable model of HCV immunopathology as well as for eval-
uation of siRNA, interferon and other cytokine therapies.
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1. Introduction
The most prominent feature of persistent hepatitis C virus
(HCV) infection is the development of chronic hepatitis in the
majority of infected individuals and the potential for disease
progression to hepatocellular carcinoma [1^4]. Unfortunately,
a number of important issues related to HCV-mediated dis-
ease progression are unknown at this time. Furthermore, nei-
ther a vaccine nor any other means of e¡ective chemotherapy
is available to control HCV infection. The chimpanzee is the
only available animal model to study HCV infection and has
been used for characterizing the virus, analyzing the infectivity
of clinical samples, and studying clinical and immunological
aspects of viral infection [5]. It is, therefore, most di⁄cult to
study the biological properties and pathogenicity of HCV.
The HCV genome contains a linear, positive-strand RNA
molecule of V9500 nucleotides [6]. A number of HCV ge-
nomes have been cloned, and the sequence divergence indi-
cates several genotypes and a series of subtypes for this virus
[7]. The HCV genome encodes a single polyprotein precursor
of V3000 amino acids [6] which is cleaved by both host and
viral proteases [8^10] generating at least 10 individual pro-
teins, Core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A
and NS5B.
NS5A exists as two phosphoproteins, p56 and p58, which
are phosphorylated at serine residues after the mature NS5A
protein is released from the polyprotein [11,12]. Although
phosphorylation of HCV NS5A occurs predominantly on ser-
ine, a low level of phosphorylation on threonine residues was
also observed [13]. Sequence comparison of the regions sur-
rounding the sites of phosphorylation indicates an extremely
high level of conservation between di¡erent strains of the
virus, but the biological signi¢cance of phosphorylation is still
unclear. NS5A localizes in the cytoplasm. In recent years,
NS5A has been intensively studied in vitro. We have shown
that NS5A has a trans-regulatory property and transcription-
ally modulates proliferating cell nuclear antigen and p21 cell
cycle regulatory genes [14], physically associates and seques-
ters p53 in the cytoplasm, represses p53-mediated p21 tran-
scription [15,16], and activates STAT3 [17]. Exogenous ex-
pression of NS5A in murine ¢broblasts transformed cells to
a tumorigenic phenotype [14,18]. NS5A also physically asso-
ciates with several cellular proteins (SNARE, SRCAP and
karyotype L), suggesting its role in cell growth regulation
[19^21]. We have shown that NS5A protects against tumor
necrosis factor-mediated apoptotic cell death [22,23]. Together
these results suggest the possible involvement of NS5A in
virus-mediated pathogenesis. Lerat et al. [24] reported trans-
genic mice expressing HCV proteins developed hepatocellular
carcinoma (HCC), and suggested that non-structural proteins
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play a role for increasing the risk of HCC. However, the role
of a speci¢c non-structural protein has not been investigated.
In this study, we have examined the role of NS5A protein-
mediated pathogenesis in transgenic mice. Here, we report the
generation of transgenic mice, expression of HCV NS5A pro-
tein, and histological ¢ndings of the liver.
2. Materials and methods
2.1. Microinjection and generation of NS5A transgenic mice
To generate a NS5A transgenic mouse model, the HCV NS5A
genomic region from genotype 1a H77 strain was directed by the
mouse major urinary promoter (MUP) for expression in mouse liver
(Fig. 1A). The pSA11 vector [25] containing MUP for expression of
the liver-speci¢c gene (kindly provided by Dr. William Held, Roswell
Park Cancer Institute, Bu¡alo, NY, USA) was used to clone the HCV
NS5A genomic region. The NruI/XbaI fragment of the cytomegalovi-
rus NS5A plasmid was excised, ¢lled in with Klenow and subcloned
into blunt-ended pSA11 vector to position the NS5A genomic region
downstream of the MUP. A polyadenylation sequence from respira-
tory syncytial virus chloramphenicol acetyltransferase was cloned at
the carboxy-terminal site of NS5A. The orientation of the resulting
transgene plasmid (pMUP-NS5A) was veri¢ed by restriction enzyme
digestion and nucleotide sequence analysis of the junctions. Potential
founders were analyzed by polymerase chain reaction (PCR) and
Southern blot from tail DNA.
2.2. Analysis of transgene expression
At least two transgenic mice (one male and one female) and their
normal littermates from each established line were killed at 8 weeks of
age. Total RNA was extracted separately from liver, heart, kidney,
lung, spleen and brain using the PUREscript kit (Gentra, Minneap-
olis, MN, USA). Reverse transcriptase (RT) PCR was performed
using NS5A-speci¢c sense (5P-GGACGATGAGGATCGTCGG-3P)
and antisense (5P-TGGCTAGCCGAGGAGCTGG-3P) primers. A
calculated size DNA band (469 bp) was visualized by electrophoretic
analysis of the RT-PCR product on agarose gel. RT-PCR for
GAPDH as an internal control was performed similarly using speci¢c
sense and antisense primers [23]. For the analysis of NS5A protein
expression, livers from transgenic mice or non-transgenic control lit-
termates were homogenized in RIPA bu¡er (0.15 M NaCl, 50 mM
Tris pH 8.0, 0.5% sodium deoxycholate, 1% NP-40 and 1% sodium
dodecyl sulfate (SDS)). Liver homogenate was clari¢ed and subjected
to SDS^polyacrylamide gel electrophoresis (PAGE) for Western blot
analysis. The blot was probed with a rabbit polyclonal antibody to
HCV NS5A (kindly provided by C. Rice, Washington University, St.
Louis, MO, USA) or monoclonal antibody to NS5A (Biogenesis,
Kingston, NH, USA) and detected by chemiluminescence (ECL,
Amersham, Piscataway, NY, USA).
2.3. Analysis of hepatocellular injury
Blood samples were collected from both transgenic mice and nor-
mal littermates. Alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) activities in serum were measured using a clinical
analyzer (Roche Cobad Mira plus). Mean values of both ALT and
AST in serum of transgenic mice were compared with those of normal
littermates. Both transgenic and normal mice at di¡erent age groups
were killed and di¡erent tissues including liver, spleen and gall bladder
were collected and ¢xed in 10% formaldehyde solution. Sections of
3^5 Wm thick were obtained from para⁄n-embedded tissues. The sec-
tions were then stained with hematoxylin and eosin and examined
under a microscope.
3. Results and discussion
To generate transgenic mice, the HCV NS5A genomic re-
gion under the control of MUP was microinjected into fertil-
Fig. 1. A: Schematic presentation of MUP-NS5A and apoE-NS5A constructs. The transgenic vector contains the mouse MUP or apoE pro-
moter elements followed by the HCV NS5A genomic region (1.3 kb) with intron and poly A signal. B: RT-PCR analysis for expression of
NS5A in transgenic mouse liver from the M7 line at 8 weeks of age. PCR product from a negative control RNA of a normal littermate (lane
1), and RNA from three di¡erent transgenic mice (lanes 2^4), were analyzed by agarose gel electrophoresis. C: RT-PCR analysis showing liver-
speci¢c NS5A expression in the M7 line (lanes 3 and 4), L11 (lanes 5 and 6), and L5 (lanes 7 and 8) at 18 months of age. Lanes 1 and 2 repre-
sent positive and negative controls, respectively, for NS5A ampli¢cation.
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ized oocytes from FVB inbred mice. Two founders containing
the MUP-HCV NS5A sequence were identi¢ed, however,
upon subsequent breeding, only one line of transgenic mice
(M7) was established, bearing approximately two copies of the
transgene as determined by Southern blot analysis (data not
shown). Generation of transgenic mouse lines expressing the
liver-speci¢c apoE promoter (kindly provided by John Taylor,
Gladstone Institute of Cardiovascular Disease, San Francisco,
CA, USA) was described previously [23]. Three lines were
established and named L1, L5 and L11. However, the L1
mouse line became infertile ; M7, L5 and L11 were fertile
and were expanded by successive backcrossing against the
FVB parental strain.
RNA isolated from control or transgenic mouse liver and
other tissues at 8 weeks of age was analyzed for expression of
the NS5A gene by RT-PCR. The results suggested expression
of NS5A-speci¢c sequence only in transgenic mouse lines, but
not in control littermates (Fig. 1B). RNA isolated from kid-
ney, spleen, brain, heart and lung of L5 and L11 lines did not
exhibit NS5A expression by RT-PCR, suggesting that the
transgene expression was restricted to the liver. Results from
this study indicated the authenticity of the transgenic mouse
line harboring the NS5A hybrid construct and expression of
mRNA in mouse liver. RNA isolated from other tissues of
transgenic mouse line M7.9 displayed NS5A expression at an
early age (2^4 weeks), however, after 6 weeks of age, NS5A
was expressed only in liver. A similar observation was re-
ported in transgenic mice expressing SV40 T antigen (reviewed
in [25]). This time period corresponds to the onset of sexual
maturity and an increase in the level of hormones. These
hormones a¡ect MUP gene expression and may play a role
in regulating MUP expression in the developmental pattern.
RNA isolated from the liver of transgenic mice at 18 months
of age displayed NS5A expression in all three transgenic
mouse lines (Fig. 1C).
For analysis of NS5A protein expression, livers from trans-
genic mice or non-transgenic control littermates at 8 weeks of
age were homogenized in RIPA bu¡er. Liver homogenate was
clari¢ed and subjected to SDS^PAGE for Western blot anal-
ysis. The blot was probed with a rabbit polyclonal antibody to
HCV NS5A or monoclonal antibody to NS5A and detected
by chemiluminescence. Expression of a V56 kDa band from
transgenic mouse liver was observed, while control mouse
liver failed to exhibit a detectable signal by chemiluminescence
(Fig. 2A). Expression of HCV NS5A protein from 18 month
old mice was also con¢rmed by Western blot analysis using a
monoclonal antibody to NS5A. Di¡erent levels of NS5A ex-
pression were observed from transgenic mouse liver (Fig. 2B)
in both M7 and L11 lines. A similar result was also observed
from L5 lines [23]. We have also performed immunohistolog-
ical staining of NS5A in transgenic mouse liver (Fig. 3). Our
results con¢rmed the expression of HCV NS5A protein in the
hepatocytes of transgenic mice, while normal littermates did
not display a detectable staining. HCV NS5A was expressed
mostly in the zone 3 (peri-central vein) hepatocytes in trans-
genic mouse liver, and the expression pattern was similar in
both transgenic mouse lines. NS5A staining was not associ-
ated with usual in£ammatory in¢ltrates.
Both transgenic and normal mice of di¡erent age groups
were killed and examined visually for any abnormalities. Dif-
ferent tissues including liver, spleen and gall bladder from
Fig. 2. A: Western blot analysis of liver homogenate from M7
(lanes 1^3), L11 (lanes 5 and 6) transgenic mice and normal litter-
mates (lanes 4 and 7) at 8 weeks of age using a polyclonal antibody
to NS5A. The molecular weight of the NS5A protein band (V56
kDa) was ascertained from the migration of standard protein molec-
ular weight markers (Invitrogen). B: Liver-speci¢c NS5A expression
in transgenic mice at 18 months of age by Western blot analysis us-
ing speci¢c antibody. The molecular weight of the NS5A band
(V56 kDa) was ascertained from the migration of standard protein
molecular weight markers (Invitrogen).
Fig. 3. Immunohistochemical analysis of HCV NS5A in liver of normal littermate (A) and transgenic mice (B) using a speci¢c monoclonal anti-
body. NS5A antibody staining was predominantly in the cytoplasm of hepatocytes. HCV NS5A was expressed mostly in the zone 3 (peri-cen-
tral vein) hepatocytes in transgenic mouse liver.
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both groups of mice were collected and ¢xed in 10% formal-
dehyde solution. Para⁄n-embedded tissue sections (3^5 Wm)
were then stained with hematoxylin and eosin and examined
under a microscope. Slides were examined by pathologists
(N.J.P. and L.T.) who were blinded to the status of the ani-
mals. In the L11 line, 32 transgenic mice of age ranging from
6 to 24 months were examined (Table 1). Three out of 32 mice
developed lung adenocarcinoma and splenic sarcoma between
16 and 24 months of age. Four mice from this transgenic line
displayed prolapsed urinary bladder and seminal vesicle
through their pelvic girdle starting from 9 to 24 months. On
the other hand, only one normal mouse out of 30 showed
urinary bladder in£ammation. However, none of the mice
examined in this transgenic line showed any abnormality in
the liver by microscopic or histological staining of formalin-
¢xed tissue sections. In the L5 line, we examined 40 mice of
di¡erent age groups. Like the L11 line, here also we observed
solid tumor in thymus and lung adenocarcinoma in ¢ve mice,
and urinary bladder in£ammation in six mice between 9 and
23 months of age. A single 8 month old transgenic animal had
macroscopically evident 0.5 mm white spots in the liver. How-
ever, no other signi¢cant abnormality was observed in histo-
pathology. Mice of the M7 line were phenotypically normal
and did not exhibit any gross liver abnormality even after 24
months of age. Three out of 40 mice examined developed
tumor in thymus and lung adenocarcinoma, and showed
V20% steatosis in liver but did not develop nodularity or
adenoma. Two mice of this line (8 months and 13 months)
showed a moderate to high level of portal, interface and lob-
ular in£ammation, but no adenoma. None of the non-hepatic
tumors from these mice displayed NS5A mRNA expression
by RT-PCR. The clinical abnormality (urinary bladder in-
£ammation) in mice was not statistically signi¢cant (Fisher’s
exact test, two-tailed P value 0.1678). Interestingly, four out
of 30 normal littermates developed lung adenocarcinoma,
which could be a genetic disease in the FVB background at
old age. Hematoxylin and eosin-stained liver sections were
scored for necroin£ammatory activity and ¢brosis by the
Scheuer [26] scale and evaluated for the presence of apoptosis,
steatosis, adenoma, dysplasia, and hepatocellular carcinoma.
No animal had hepatocellular carcinoma or hepatic adenoma.
Cirrhosis or ¢brosis was not observed. The Scheuer activity
score was not signi¢cantly di¡erent between the individual
transgenic lines and the pooled littermate controls (L5 trans-
genic, mean activity score 1.560, n=40; L11 transgenic, mean
activity score 1.318, n=32; M7 transgenic, mean activity
score 1.414, n=40; normal littermate controls, mean activity
1.545, n=30; Mann^Whitney test, two-tailed P values 0.6022,
0.6824, and 0.8766). A representative histopathology of 18
month old mouse liver from each transgenic line and from
normal littermate control is shown in Fig. 4. We also exam-
ined the serum ALT and AST activities. Blood samples were
collected at 6 and 18 months of age from both transgenic and
normal littermates. ALT/AST activities in serum were mea-
sured using a clinical analyzer (Roche Cobad Mira plus).
Mean values of both ALT and AST in serum of transgenic
Table 1
Summary of HCV NS5A transgenic mouse lineages
Transgenic line Number of mice
examined
Age group
(months)
Liver
abnormalities
Tumor in other
organs
Urinary bladder
in£ammation
L11 32 6^24 None 3 4
L5 40 6^23 None 5 6
M7 40 6^24 None 3 2
Normal 30 6^24 None 4 1
Fig. 4. Histological analysis of liver from normal and transgenic mice. Hematoxylin and eosin-stained para⁄n sections of liver histology from
normal littermates (N), transgenic mice M7, L5 and L11 are shown at 20U.
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mice and normal littermates did not exhibit detectable di¡er-
ences.
Chronic HCV infection may eventually lead to HCC and
viral protein(s) are likely to be one of the contributing factors.
Success in understanding HCV-mediated pathogenesis and in
controlling HCV infection has been impaired in part because
of the unavailability of an e⁄cient cell culture system for virus
growth and a convenient small animal model. Advances in the
¢eld of transgenic technology o¡ered us a unique opportunity
to develop valuable rodent models for human diseases. We
and others have shown that HCV NS5A plays an important
role in transcriptional regulation of cell cycle regulatory genes
as well as in the inhibition of apoptosis [14,15,18,23,27,28].
Functional p53 is a positive regulator of apoptosis. Viral pro-
teins that bind p53 contribute to immortalization or are them-
selves immortalizing [29], and ¢broblasts from mice that are
de¢cient in p53 are immortalized readily [30]. Invalidation of
the apoptosis mechanism is an important step in tumor devel-
opment, and the same may be true for immortalization [31].
Therefore, we examined whether NS5A has a role in promot-
ing tumor formation in transgenic mouse liver. Our results
suggest that despite di¡erent expression levels of NS5A, trans-
genic mouse liver of FVB genetic background did not develop
liver abnormalities. This may be due to a number of other
contributing factors, including genetic background of the
mouse strain used for generating transgenic animals [24,32^
34].
We do not know at present whether NS5A promotes im-
mortalization of primary murine hepatocytes as an initial
event associated with the multi-step phenomenon of cancer.
For example, expression of cyto-MET or transforming growth
factor-K in transgenic mice does not develop tumor, but im-
mortalizes hepatocytes [35^37]. Immortalized culture was also
established from transgenic mice of hepatitis B virus [38].
Therefore, it is possible that expression of HCV NS5A protein
may trigger the neoplastic events in the presence of other viral
proteins as observed by Lerat et al. [24]. Although liver patho-
genesis was not observed with NS5A transgenic mice, none-
theless, these animals will be a valuable model of HCV-related
immunopathology, as well as for evaluation of antiviral thera-
pies.
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